Latest filing published 17 Aug 2026 for ZEVRA THERAPEUTICS, INC., €411k.
Filing timeline
BuySaleInsider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Rahsaan Thompson: trading record in brief
Rahsaan Thompson (board member) discloses dealings in 2 companies, chiefly Zevra Therapeutics, Inc. and Gritstone bio, Inc. We count 7 filings; the first trade dates from 7 January 2021 and the latest from 14 August 2026.
Sales make up the whole of the open-market record (3 sales, €631k). Outside the open market, there are 2 share grants and 2 option exercises. In 2026 alone, the filings show no purchases and 2 sales.
The latest filing, published on 17 August 2026, reports an open-market sale of €411k in Zevra Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Rahsaan Thompson
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 42,666 shares@ US$11.12770.071% mcap68.5% of flowCommon StockSEC:0001434647-26-000073:0
- 11,333 sharesCommon StockSEC:0001788524-26-000002:0
- 24,000 shares@ US$9.2085100.0% of flowCommon StockSEC:0001437749-25-021577:0
- 66,666 sharesCommon StockSEC:0001437749-25-021183:0
- 19,240 shares0Common StockSEC:0001567619-22-008723:0
- 25,500 shares0Common StockSEC:0001567619-21-020875:0
6 of 6 declarations